Soliris Eculizumab Injection

1. Indications and Usage
Paroxysmal Nocturnal Hemoglobinuria (PNH):
Indicated for the treatment of PNH to reduce hemolysis.
Atypical Hemolytic Uremic Syndrome (aHUS):
Indicated for the treatment of aHUS to inhibit complement-mediated thrombotic microangiopathy (TMA).
Generalized Myasthenia Gravis (gMG):
Indicated for the treatment of adult patients who are anti-acetylcholine receptor (AchR) antibody-positive.
Neuromyelitis Optica Spectrum Disorder (NMOSD):
Indicated for the treatment of adult patients who are anti-aquaporin-4 (AQP4) antibody-positive.
2. Dosage and Administration
Route of Administration:
Intravenous (IV) Infusion ONLY. Do not administer as an IV push or bolus.
Adult Dosage (PNH):
Loading: 600 mg weekly for the first 4 weeks.
Maintenance: 900 mg on Week 5, then 900 mg every 2 weeks thereafter.
Adult Dosage (aHUS / gMG / NMOSD):
Loading: 900 mg weekly for the first 4 weeks.
Maintenance: 1200 mg on Week 5, then 1200 mg every 2 weeks thereafter.
Pre-treatment Requirement:
Patients must be vaccinated against Neisseria meningitidis at least 2 weeks prior to the first dose.
3. Mechanism of Action
Complement C5 Inhibition:
Eculizumab is a humanized monoclonal antibody that binds with high affinity to the complement protein C5.
Physiological Effect:
It inhibits the cleavage of C5 into C5a and C5b, thereby preventing the formation of the terminal complement complex C5b-9 (Membrane Attack Complex).
4. Safety and Warnings
Serious Meningococcal Infections (BLACK BOX WARNING):
Eculizumab increases the risk of systemic meningococcal infections, which can be fatal if not recognized early.
Infusion Reactions:
May occur during or within 24 hours of infusion. Monitor for symptoms like headache, hypertension, or dyspnea.
Vaccination Considerations:
Vaccination may further activate complement; monitor for disease exacerbation after vaccination.
Adverse Reactions
Most Common:
Headache, nasopharyngitis, diarrhea, nausea, fatigue, and hypertension (specifically in aHUS).
Infections:
Increased susceptibility to infections, particularly encapsulated bacteria (e.g., Streptococcus pneumoniae, Haemophilus influenzae).
6. Drug Interactions
Live Vaccines:
Avoid the use of live bacterial or viral vaccines during treatment.
No Significant Metabolic Interactions:
As a monoclonal antibody, it does not interact with CYP450 enzymes.
7. Pharmaceutical Information
Chemical Composition:
Active Ingredient: Eculizumab.
Storage:
Store in a refrigerator at 2-8°C. Do not freeze or shake. Protect from light.